(0.62%) 5 078.00 points
(0.46%) 38 246 points
(0.74%) 17 568 points
(0.29%) $79.23
(1.81%) $1.967
(-0.64%) $2 296.30
(-1.71%) $26.29
(0.65%) $961.10
(0.20%) $0.935
(0.37%) $11.07
(0.14%) $0.800
(-1.47%) $91.89
3 days till quarter result
(bmo 2024-05-05)
Expected move: +/- 0.00%
1.99% € 84.70
Live Chart Being Loaded With Signals
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...
Stats | |
---|---|
Volumen de hoy | 1 178.00 |
Volumen promedio | 1 292.00 |
Capitalización de mercado | 20.14B |
EPS | €0 ( 2024-03-20 ) |
Próxima fecha de ganancias | ( €11.56 ) 2024-05-05 |
Last Dividend | €2.13 ( 2022-06-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | 22.11 |
ATR14 | €0.299 (0.35%) |
BioNTech SE Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BioNTech SE Finanzas
Annual | 2023 |
Ingresos: | €3.82B |
Beneficio Bruto: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2023 |
Ingresos: | €3.82B |
Beneficio Bruto: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2022 |
Ingresos: | €17.31B |
Beneficio Bruto: | €12.78B (73.82 %) |
EPS: | €38.08 |
FY | 2021 |
Ingresos: | €18.98B |
Beneficio Bruto: | €15.12B (79.66 %) |
EPS: | €40.63 |
Financial Reports:
No articles found.
BioNTech SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €2.13 | 2022-06-02 |
Last Dividend | €2.13 | 2022-06-02 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | €2.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.82 | -- |
Div. Sustainability Score | 9.73 | |
Div.Growth Potential Score | 2.32 | |
Div. Directional Score | 6.02 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WIB.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
EVK.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
PAT.DE | Ex Dividend Junior | 2023-05-26 | Sporadic | 0 | 0.00% | |
ALD.DE | Ex Dividend Knight | 2023-08-10 | Quarterly | 0 | 0.00% | |
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
SAP.DE | Ex Dividend Knight | 2023-05-12 | Annually | 0 | 0.00% | |
BST.DE | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
KBX.DE | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% | |
TNE5.DE | Ex Dividend Junior | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.244 | 1.500 | 5.13 | 7.69 | [0 - 0.5] |
returnOnAssetsTTM | 0.0404 | 1.200 | 8.65 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0464 | 1.500 | -0.596 | -0.894 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.12 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00952 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 5.58 | 1.000 | 9.04 | 9.04 | [3 - 30] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 0.186 | 0.373 | [0 - 20] |
debtEquityRatioTTM | 0.0108 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.527 | 1.000 | 4.54 | 4.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.181 | 1.000 | 8.38 | 8.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 24.52 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.166 | 0.800 | -2.23 | -1.781 | [0.5 - 2] |
Total Score | 9.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.22 | 1.000 | 7.96 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0464 | 2.50 | -0.383 | -0.894 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 3.46 | 0.373 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0696 | 1.500 | -3.80 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 1.406 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.32 |
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico